{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:06:19Z","timestamp":1791162379343,"version":"4.1.0"},"reference-count":138,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.clinthera.2015.09.001","type":"journal-article","created":{"date-parts":[[2015,9,27]],"date-time":"2015-09-27T15:03:06Z","timestamp":1443366186000},"page":"2153-2179","source":"Crossref","is-referenced-by-count":46,"title":["Nonstatin Therapies for Management of Dyslipidemia: A Review"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01492361","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01663402","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01687998","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01764633","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01975376","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01975389","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02104817","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Karen R.","family":"Sando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.09.001_bib1","unstructured":"National Center for Chronic Disease Prevention and Health Promotion. Heart Disease and Stroke Prevention: Addressing the National\u2019s Leading Killers. At a Glance (2011). Centers for Disease Control. http:\/\/198.246.124.29\/chronicdisease\/resources\/publications\/aag\/pdf\/2011\/heart-disease-and-stroke-aag-2011.pdf. Accessed April 20, 2015."},{"key":"10.1016\/j.clinthera.2015.09.001_bib2","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 \u2013 Executive Summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib4","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"N\u20133 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Parish","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib8","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.clinthera.2015.09.001_bib12","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib13","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1001\/jama.1990.03450230049028","article-title":"Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up","volume":"264","author":"Cashin-Hemphill","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib14","first-page":"599","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"325","author":"Brown","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib15","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib16","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib17","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib19","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1074248410361337","article-title":"Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease","volume":"15","author":"Duggal","year":"2010","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib21","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1161\/STROKEAHA.113.001529","article-title":"Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease\u2013the Atherothrombosis Intervention in Metabolic Syndrome with low HDL\/high triglycerides: impact on global health outcome (AIM-HIGH) trial","volume":"44","author":"Teo","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2015.09.001_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib24","first-page":"681","article-title":"Overview of omega-3 fatty acid therapies","volume":"38","author":"Bradberry","year":"2013","journal-title":"PT"},{"key":"10.1016\/j.clinthera.2015.09.001_bib25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacc.2009.02.084","article-title":"Omega-3 polyunsaturated fatty acids and cardiovascular diseases","volume":"54","author":"Lavie","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib27","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1210\/jc.2011-3213","article-title":"Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline","volume":"97","author":"Berglund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.09.001_bib28","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.amjcard.2005.07.071","article-title":"Usefulness of omega-3 fatty acids and the prevention of coronary heart disease","volume":"96","author":"Harper","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajcn\/84.1.5","article-title":"n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review","volume":"84","author":"Wang","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clinthera.2015.09.001_bib30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11883-010-0137-0","article-title":"Alpha-linolenic acid: is it essential to cardiovascular health?","volume":"12","author":"Geleijnse","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2015.09.001_bib31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/met.2011.0004","article-title":"Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database","volume":"9","author":"Zargar","year":"2011","journal-title":"Metab Syndr Relat Disord"},{"key":"10.1016\/j.clinthera.2015.09.001_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.11.2828","article-title":"Overview of prescription omega-3 fatty acid products for hypertriglyceridemia","volume":"126","author":"Weintraub","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(89)90828-3","article-title":"Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART)","volume":"2","author":"Burr","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the gissi-prevenzione trial. Gruppo Italiano per lo Studio Della Sopravvivenza Nell\u2019infarto Miocardico","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.ejcn.1601539","article-title":"Lack of benefit of dietary advice to men with angina: results of a controlled trial","volume":"57","author":"Burr","year":"2003","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clinthera.2015.09.001_bib36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib37","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMoa1003603","article-title":"N-3 fatty acids and cardiovascular events after myocardial infarction","volume":"363","author":"Kromhout","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib39","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.110.948562","article-title":"OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction","volume":"122","author":"Rauch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib40","doi-asserted-by":"crossref","first-page":"c6273","DOI":"10.1136\/bmj.c6273","article-title":"Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial","volume":"341","author":"Galan","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.09.001_bib41","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"The ORIGIN Trial Investigators. n\u20133 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib42","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.287.14.1815","article-title":"Fish and omega-3 fatty acid intake and risk of coronary heart disease in women","volume":"287","author":"Hu","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jama.279.1.23","article-title":"Fish consumption and risk of sudden cardiac death","volume":"279","author":"Albert","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib44","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/heartjnl-2013-305257","article-title":"\u03c9-3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle","volume":"100","author":"Wu","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2015.09.001_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10557-011-6306-8","article-title":"Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials","volume":"25","author":"Chen","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003205.pub2","article-title":"Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus","author":"Hartweg","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2015.09.001_bib47","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/2012.jama.11374","article-title":"Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis","volume":"308","author":"Rizos","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/archinternmed.2012.262","article-title":"Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials","volume":"172","author":"Kwak","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib49","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/CIRCOUTCOMES.112.966168","article-title":"Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis","volume":"5","author":"Kotwal","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.clinthera.2015.09.001_bib50","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12325-010-0033-6","article-title":"Systematic review on evidence of the effectiveness of cholesterol-lowering drugs","volume":"27","author":"Gupta","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2261-10-24","article-title":"Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials","volume":"10","author":"Filion","year":"2010","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2015.09.001_bib52","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2261-14-70","article-title":"The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis","volume":"14","author":"Enns","year":"2014","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.clinthera.2015.09.001_bib53","doi-asserted-by":"crossref","first-page":"e6698","DOI":"10.1136\/bmj.e6698","article-title":"Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis","volume":"345","author":"Chowdhury","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.09.001_bib54","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1472-8206.2004.00268.x","article-title":"Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials","volume":"18","author":"Yzebe","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003177.pub2","article-title":"Omega 3 fatty acids for prevention and treatment of cardiovascular disease","author":"Hooper","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2015.09.001_bib56","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinte.165.7.725","article-title":"Effect of different antilipidemic agents and diets on mortality: a systematic review","volume":"165","author":"Studer","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib57","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/07853890802698834","article-title":"Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials","volume":"41","author":"Zhao","year":"2009","journal-title":"Ann Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib58","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1017\/S0007114512001596","article-title":"Long chain omega-3 fatty acids and cardiovascular disease: a systematic review","volume":"107","author":"Delgado-Lista","year":"2012","journal-title":"Br J Nutr"},{"key":"10.1016\/j.clinthera.2015.09.001_bib59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1160\/TH10-01-0008","article-title":"Exploring newer cardioprotective strategies: n-3 fatty acids in perspective","volume":"104","author":"Di Minno","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2015.09.001_bib60","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11936-011-0128-7","article-title":"The use of fibric acid derivatives in cardiovascular prevention","volume":"13","author":"Khoury","year":"2011","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib61","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11883-013-0390-0","article-title":"Cardiometabolic impact of non-statin lipid lowering therapies","volume":"16","author":"Goyal","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.clinthera.2015.09.001_bib62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","article-title":"Combined therapy in the treatment of dyslipidemia","volume":"24","author":"Reiner","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib64","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib65","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib66","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib67","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/bmj.4.5790.767","article-title":"Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region","volume":"4","author":"Arthur","year":"1971","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.09.001_bib68","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bmj.4.5790.775","article-title":"Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians","volume":"4","year":"1971","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.09.001_bib69","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0021-9150(72)90067-6","article-title":"Controlled trial of clofibrate in cerebral vascular disease","volume":"15","author":"Acheson","year":"1972","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib70","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/01.STR.4.4.684","article-title":"The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section","volume":"4","year":"1973","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2015.09.001_bib71","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"10.1016\/j.clinthera.2015.09.001_bib72","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2337\/diacare.14.4.308","article-title":"Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM","volume":"14","author":"Hanefeld","year":"1991","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.09.001_bib73","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.CIR.92.7.1779","article-title":"Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study","volume":"92","author":"Tenkanen","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib74","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib76","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1185\/030079906X89865","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials","volume":"22","author":"Allemann","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2015.09.001_bib77","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib78","doi-asserted-by":"crossref","first-page":"962.e1","DOI":"10.1016\/j.amjmed.2009.03.030","article-title":"Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review","volume":"122","author":"Abourbih","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib79","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2015.09.001_bib80","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/M13-2526","article-title":"Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy","volume":"160","author":"Gudzune","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib81","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/archinte.165.7.725","article-title":"Effect of different antilipidemic agents and diets on mortality: a systematic review","volume":"165","author":"Studer","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib82","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib83","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/archinte.163.6.669","article-title":"Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials","volume":"163","author":"Corvol","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-13-1","article-title":"Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention","volume":"13","author":"Zhou","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib85","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib87","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009753","article-title":"Fibrates for primary prevention of cardiovascular disease events","author":"Nordmann","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2015.09.001_bib88","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/BF03216291","article-title":"Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism","volume":"40","author":"Einarsson","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib89","unstructured":"Monroe AK, Gudzune KA, Sharma R, et al. Combination Therapy Versus Intensification of Statin Monotherapy: An Update, Comparative Effectiveness Review No 132. AHRQ Publication No. 14-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2014. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK189822\/. Accessed April 22, 2015."},{"key":"10.1016\/j.clinthera.2015.09.001_bib90","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.amjcard.2006.08.063","article-title":"Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice","volume":"99","author":"Kamal-Bahl","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib91","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib92","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0021-9681(78)90076-0","article-title":"Colestipol hydrochloride in hypercholesteroleamic patients- effect on serum cholesterol and mortality","volume":"31","author":"Dorr","year":"1978","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib93","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9149(99)80523-2","article-title":"Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy","volume":"75","author":"Schrott","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib94","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib95","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib96","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.1993.00410110029006","article-title":"Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia","volume":"153","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib97","first-page":"427","article-title":"Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites","volume":"12","author":"Ismail","year":"1990","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib98","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ddr.430270309","article-title":"Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type II hypercholesterolemia","volume":"27","author":"Barbi","year":"1992","journal-title":"Drug Development Res"},{"key":"10.1016\/j.clinthera.2015.09.001_bib99","first-page":"39","article-title":"Low-dose combination therapy with colestipol and simvastatin in patients with moderate to severe hypercholesterolemia","volume":"5","author":"Johansson","year":"1995","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib100","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/157016111793744760","article-title":"Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years","volume":"9","author":"Lioudaki","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248412445506","article-title":"Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study","volume":"18","author":"Kouvelos","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.09.001_bib102","doi-asserted-by":"crossref","first-page":"622","DOI":"10.7326\/0003-4819-151-9-200911030-00144","article-title":"Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia","volume":"151","author":"Sharma","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib103","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/imj.12706","article-title":"Safety and coadministration of ezetimibe and statins in patients with hypercholesterolemia: a meta-analysis","volume":"45","author":"Luo","year":"2015","journal-title":"Intern Med J"},{"key":"10.1016\/j.clinthera.2015.09.001_bib104","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.amjcard.2006.10.064","article-title":"Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study","volume":"99","author":"Rossebo","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib105","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib106","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib107","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-157-4-201208210-00005","article-title":"Lipid-lowering therapy in persons with chronic kidney disease","volume":"157","author":"Upadhyay","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib108","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/01.ATV.0000214979.24518.95","article-title":"Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?","volume":"26","author":"Rensen","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib110","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib111","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":"Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib112","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":"Effect of torcetrapib on the progression of coronary atherosclerosis","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib113","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib114","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(11)61383-4","article-title":"Safety and efficacy of dalcetrapib on atherosclerotic disease using non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial","volume":"378","author":"Fayad","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"L\u00fcscher","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2015.09.001_bib116","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib117","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib118","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1194\/jlr.M007468","article-title":"Biochemical characterization of cholesteryl ester transfer protein inhibitors","volume":"51","author":"Ranalletta","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.001_bib119","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(07)61813-3","article-title":"Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies","volume":"370","author":"Krishna","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib120","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ahj.2008.09.022","article-title":"Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients","volume":"157","author":"Bloomfield","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.clinthera.2015.09.001_bib121","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.clinthera.2015.09.001_bib122","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib123","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib124","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/MCA.0000000000000113","article-title":"Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia","volume":"25","author":"Stawowy","year":"2014","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.vph.2014.03.004","article-title":"Risk prediction with proprotein convertase subtilisin\/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment","volume":"62","author":"Werner","year":"2014","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib126","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2014.10.018","article-title":"Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 levels in patients with dyslipidemia","volume":"115","author":"Khera","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib127","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.acvd.2013.10.007","article-title":"PCSK9: From discovery to therapeutic applications","volume":"107","author":"Farnier","year":"2014","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","article-title":"The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway","volume":"228","author":"Catapano","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2015.09.001_bib129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"Stein","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib130","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib131","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib132","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib133","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2015.09.001_bib134","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2015.09.001_bib135","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2015.09.001_bib136","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2015.09.001_bib137","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2015.09.001_bib138","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815010930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T11:03:17Z","timestamp":1582542197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815010930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":138,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0149291815010930"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.09.001","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}